drugset / Trial / NCT01700387

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387

Phase 4 Completed 20 enrolled Cady, Roger, M.D. Allergan · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate sustained tolerability, quality of life, and change in cognitive efficiency following treatment with OnabotulinumtoxinA and daily topiramate vs. OnabotulinumtoxinA and daily placebo (Group A vs. Group B).

Timeline

Start
2012-10
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 50 mg
Background Botulinum toxin type A Protein / enzyme biologic 155 unknown Intramuscular

Indications